CCNE1

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Jeudi, mai 9, 2024
Transfer, FDA, Research, Inflammation, Cell cycle, IND, CNS, Prostate cancer, AACR, Cancer, Autoimmunity, Lung cancer, Traffic barrier, MGD, Food, European Alliance, Conference, Roche, DDW, Pericarditis, Therapy, NSCLC, Rat, Ulcerative colitis, Poster, NLRP3, CCNE1, SCLC, Finance, Triple-negative breast cancer, Consultant, Public expenditure, Obesity, Gout, GLP, DSM-IV codes, Clinical trial, Toxicology, CDK2, G&A, Investigational New Drug, MYC, Research and development, EULAR, Carcinoma, Administration, Rheumatoid arthritis, Neoplasm, POC, Dermatology, Growth, Pharmaceutical industry

“We’re excited by the significant advances made across our entire portfolio, including both our oncology and immunology/inflammation programs,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

Key Points: 
  • “We’re excited by the significant advances made across our entire portfolio, including both our oncology and immunology/inflammation programs,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • The Company is on track to determine the recommended Phase 2 dose (RP2D) in Q2 2024 and report Phase 1 study results in H2 2024.
  • Announce the recommended Phase 2 dose for the MRT-2359 Phase 1/2 study in Q2 2024 and report Phase 1 clinical results in H2 2024.
  • Net Loss: Net loss for the first quarter of 2024 was $32.0 million, compared to $33.3 million for the fourth quarter of 2023.

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Mardi, mai 7, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Net, Safety, Food, Irinotecan, CCNE1, PPP2R1A, Lung cancer, BID, ESMO, Adolescence, PLK4, PKMYT1, Data, Bristol Myers Squibb, Patient, WEE1, FBXW7, Biomarker, Clinical trial, Annual general meeting, Therapy, NSCLC, FOLFIRI, G&A, Pharmaceutical industry

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.
  • “This was a quarter of clinical progress as we await key, near-term data on a rich set of distinctive clinical approaches for our four wholly-owned compounds in 2024,” said Lloyd M. Segal, President and Chief Executive Officer of Repare.
  • We are seeing continuing trends of patient response and benefit, and we are on track to report the updated dataset in the fourth quarter of 2024.
  • The increase in revenue for the three-month period was primarily due to the $40.0 million Roche milestone achievement in the first quarter of 2024.

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Retrieved on: 
Mercredi, avril 10, 2024
FDA, Safety, Pharmacokinetics, Infrared spectroscopy correlation table, RECIST, CCNE1, Index, Cohort, Glioblastoma, Secondary, G12, MPH, WEE1, CCNE2, Serum, Aes, FBXW7, MD Anderson Cancer Center, ATR, Day, Pharmacodynamics, Pharmaceutical industry

DOYLESTOWN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today released details about four poster presentations at the ongoing American Association of Cancer Research (AACR) Annual Meeting, taking place April 5 to 10, 2024 in San Diego, CA. The posters feature APR-1051, Aprea’s next-generation inhibitor of WEE1 kinase, as well as a clinical update on ATRN-119, its novel macrocyclic ATR inhibitor. The Company also presented a poster highlighting a new set of preclinical data in glioblastoma with a next-generation macrocyclic ATR inhibitor, ATRN-333.

Key Points: 
  • Part 1 will be dose escalation and is expected to enroll up to 39 patients with advanced solid tumors harboring cancer-associated gene alterations.
  • ATRN-119 continues to be safe and well tolerated, with no dose-limiting toxicities and no signs of significant hematological toxicity reported.
  • Pharmacokinetic studies show ATRN-119 serum concentrations are entering the expected therapeutic range at the current highest dose level (550 mg).
  • Convection-enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma.

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mercredi, février 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, CCNE1, Quarter, Adolescence, Research, Arm, PPP2R1A, PARP, FBXW7, Net, FOLFIRI, AACR, Conference, BMS, ADP, PLK4, Clinical trial, Safety, Therapy, Patient, RECIST, Nature Medicine, IND, ATR, WEE1, Partnership, Pharmaceutical industry

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Repare will sponsor the global clinical trial as a new arm in the ongoing MYTHIC trial, with costs being shared equally by Debiopharm and Repare.
  • Disclose additional camonsertib clinical development plans beyond the TRESR and ATTACC clinical trials sponsored by Repare in the second quarter of 2024.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash, cash equivalents, and marketable securities: Cash, cash equivalents, and marketable securities as of December 31, 2023 were $223.6 million.

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Lundi, janvier 8, 2024
Biotechnology, Pharmaceutical, Health, CCNE1, Conference, Dermatology, CCNE, CDK2, BID, Ovarian cancer, Research, Graft-versus-host disease, Oncology, Q&A, Polycythemia, Week, GVHD, Growth, Inflammation, Patient, Safety, Pancreatic serous cystadenoma, Autoimmunity

Incyte (Nasdaq:INCY) will highlight growth opportunities and provide key updates across its investigational pipeline and commercial portfolio during a presentation today at 7:30 a.m. PT at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Key Points: 
  • Incyte (Nasdaq:INCY) will highlight growth opportunities and provide key updates across its investigational pipeline and commercial portfolio during a presentation today at 7:30 a.m. PT at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
  • The overall safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed.
  • The Company intends to provide additional financial guidance and updates on key clinical programs during its 2023 fourth quarter and year-end earnings conference call.
  • The J.P. Morgan Healthcare Conference presentation and Q&A session can be accessed at investor.incyte.com .

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Retrieved on: 
Lundi, janvier 8, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Data Management, Technology, Genetics, Clinical Trials, Immunotherapy, CCNE1, Conference, AACR, ATR, Partnership, Debiopharm, Arm, RECIST, Adolescence, FOLFIRI, WEE1, PPP2R1A, Therapy, PARP, RLT, Nature Medicine, Clinical trial, ADP, FBXW7, Patient, Safety, PLK4, Pharmaceutical industry

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024.
  • Repare will sponsor the global study as a new arm in the ongoing MYTHIC study with costs being shared equally by Debiopharm and Repare.
  • Initiation of a Phase 1 dose finding study of RP-3467, a potential best-in-class Polθ inhibitor, in the second half of 2024.
  • Repare ended 2023 with approximately $223 million in cash, cash equivalents and marketable securities, which is anticipated to fund planned operations into mid-2026.

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

Retrieved on: 
Jeudi, janvier 4, 2024
Patient, CCNE1, Conference, AACR, CDK2, IND, Breast cancer, Drug development, SAN, Therapy, Cancer, CDK, CDK1, Toxicity, Pharmaceutical industry

SAN DIEGO, Calif. and NATICK, Mass., Jan. 4, 2024 /PRNewswire/ -- Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China). As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.

Key Points: 
  • (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China).
  • As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.
  • "With this agreement, we have laid the foundation for our potentially best-in-class oncology pipeline," said Athena Countouriotis, M.D., co-founder, president and CEO of Avenzo.
  • Allorion disclosed select data in poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023.

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

Retrieved on: 
Jeudi, janvier 4, 2024
Patient, CCNE1, Conference, AACR, CDK2, IND, Breast cancer, Drug development, SAN, Therapy, Cancer, CDK, CDK1, Toxicity, Pharmaceutical industry

SAN DIEGO, Calif. and NATICK, Mass., Jan. 4, 2024 /PRNewswire/ -- Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China). As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.

Key Points: 
  • (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China).
  • As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.
  • "With this agreement, we have laid the foundation for our potentially best-in-class oncology pipeline," said Athena Countouriotis, M.D., co-founder, president and CEO of Avenzo.
  • Allorion disclosed select data in poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023.

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

Retrieved on: 
Jeudi, janvier 4, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CCNE1, Conference, AACR, CDK2, IND, Breast cancer, Drug development, Therapy, Cancer, CDK, CDK1, Toxicity, Patient, Pharmaceutical industry

Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China).

Key Points: 
  • Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China).
  • As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.
  • “With this agreement, we have laid the foundation for our potentially best-in-class oncology pipeline,” said Athena Countouriotis, M.D., co-founder, president and CEO of Avenzo.
  • Allorion disclosed select data in poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Jeudi, novembre 9, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Research, PRS, Carboplatin, Ovarian cancer, Trae Waynes, Traveller Alien Module 2: K'kree, Oncology nursing, Partnership, CBR, September 5, ATR, CCNE1, Circulating tumor DNA, OR, BMS, Paclitaxel, Ono, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Glomus tumor, Roche, Net, Safety, Therapy, Cancer, Patient, DNA, MRR, Conference, Clinical trial, Anemia, IST, AACR, Red Barricades: ASL Historical Module 1, FOLFIRI, Genotype, PPP2R1A, PKMYT1, FBXW7, Princess Margaret Cancer Centre, RECIST, Modularity, PARP, Pharmaceutical industry, Vaccine, Reinsurance, Reparenting, G&A, IND

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.